Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
March 3, 2016
A flutuating open expected; RegMed sector, equities jumped on lower volume
March 2, 2016
RegMed’s close: a second up day
February 24, 2016
RegMed’s close: sector reversed earlier losses to finish higher
February 23, 2016
RegMed’s close: finding a bottom is a habitual process
February 16, 2016
RegMed’s close: the windsock shows the direction and strength of the wind
February 12, 2016
Higher open expected; after testing lows, we've still not found a bottom
February 9, 2016
Regenerative Medicine Earnings Scorecard - Q4/2015
February 8, 2016
RegMed’s close: Investors are selling first and questioning decisions later; knowing they can buy back-in … CHEAPER!
February 3, 2016
Cesca Therapeutics (KOOL) pulls a rabbit from the hat
January 29, 2016
RegMed’s close: buying the dips and covering shorts captures short-term momentum and volatility.
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.